Browsing: Clinical Trials & R&D

Novo Nordisk GLP-1 trials did not meet primary endpoints in Alzheimer’s studies, impacting potential neurodegeneration treatment.

J&J Alzheimer’s trial failure with posdinemab dims hopes for new treatments.

Novo Nordisk’s semaglutide failed in two Alzheimer’s trials, impacting stock by 10%.

Novo Nordisk Alzheimer’s trial with semaglutide fails to slow disease progression in over 3,800 patients.

Contineum MS trial failure leads to a significant share drop, affecting Johnson & Johnson’s interest.

Novo Nordisk is set to release pivotal Phase 3 data on semaglutide’s impact on Alzheimer’s, potentially reshaping treatment.

Novo Nordisk is set to reveal results of its semaglutide study for Alzheimer’s, potentially expanding its indications.

Agios Pyrukynd results show mixed outcomes in a crucial sickle cell study, affecting the drug’s commercial outlook.

Roche giredestrant study demonstrates significant benefits in early breast cancer, marking a milestone with its oral SERD in the adjuvant setting.

Merck Winrevair heart study demonstrates significant improvement in blood flow for heart failure patients.